Enhanced anti-tumor and anti-metastatic activity of quercetin using pH-sensitive Alginate@ZIF-8 nanocomposites: in vitro and in vivo study

被引:2
|
作者
Rostamkhani, Neda [1 ,2 ]
Salimi, Maryam [1 ,2 ]
Adibifar, Arghavan [1 ,2 ]
Karami, Zahra [2 ,3 ]
Agh-Atabay, Abdol-Hakim [4 ]
Rostamizadeh, Kobra [1 ,5 ]
Abdi, Zahra [6 ]
机构
[1] Zanjan Univ Med Sci, Sch Pharm, Dept Pharmaceut Biomat, Zanjan, Iran
[2] Zanjan Univ Med Sci, Pharmaceut Nanotechnol Res Ctr, Zanjan, Iran
[3] Zanjan Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, Zanjan, Iran
[4] Bahar Clin & pathol Lab, Zanjan, Iran
[5] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Dept Pharmacol, Seattle, WA 98195 USA
[6] Zanjan Univ Med Sci, Sch Med, Dept Anat Sci, Zanjan, Iran
关键词
zeolitic imidazolate frameworks; quercetin; alginate; pH-sensitive drug delivery; breast cancer; ZEOLITIC IMIDAZOLATE FRAMEWORKS; METAL-ORGANIC FRAMEWORK; DRUG-DELIVERY; PHYSICOCHEMICAL PROPERTIES; THERMAL-STABILITY; HYALURONIC-ACID; NANOPARTICLES; ZIF-8; ALGINATE; RELEASE;
D O I
10.1088/1361-6528/ad713f
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Quercetin (Qc) possesses anti-cancer properties, such as cell signaling, growth suppression, pro-apoptotic, anti-proliferative, and antioxidant effects. In this study, we developed an alginate-modified ZIF-8 (Alg@ZIF-8) to enhance the anti-tumor efficacy of Qc. The developed alginate-modified quercetin-loaded ZIF-8 (Alg@Qc@ZIF-8) was characterized using scanning electron microscope (SEM), dynamic light scattering (DLS), fourier transform infrared spectroscopy Thermogravimetric analysis, Brunauer-Emmett-Teller, and x-ray diffraction. The drug release pattern was evaluated at pH 5.4 and 7.4. The cytotoxicity of nanoparticles was assessed on the 4T1 cell line. Finally, the anti-tumor activity of Alg@Qc@ZIF-8 was evaluated in 4T1 tumor-bearing mice. SEM showed that the nanoparticles were spherical with a diameter of mainly below 50 nm. The DLS showed that the developed nanoparticles' hydrodynamic diameter, zeta potential, and polydispersity index were 154.9 +/- 7.25 nm, -23.8 +/- 5.33 mV, and 0.381 +/- 0.09, respectively. The drug loading capacity was 10.40 +/- 0.02%. Alg@Qc@ZIF-8 exhibited pH sensitivity, releasing more Qc at pH 5.4 (about 3.62 times) than at pH 7.4 after 24 h. Furthermore, the IC50 value of Alg@Qc@ZIF-8 on the 4T1 cell line was 2.16 times lower than net Qc. Importantly, in tumor-bearing mice, Alg@Qc@ZIF-8 demonstrated enhanced inhibitory effects on tumor growth and lung metastasis compared to net Qc. Considering the in vitro and in vivo outcomes, Alg@Qc@ZIF-8 might hold great potential for effective breast cancer management.
引用
收藏
页数:17
相关论文
共 36 条
  • [21] Anti-Tumor Activity of Eurycoma longifolia Root Extracts against K-562 Cell Line: In Vitro and In Vivo Study
    Al-Salahi, Omar Saeed Ali
    Ji, Dan
    Majid, Amin Malik Shah Abdul
    Kit-Lam, Chan
    Abdullah, Wan Zaidah
    Zaki, Abdelhamid
    Din, Shah Kamal Khan Jamal
    Yusoff, Narazah Mohd
    Majid, Aman Shah Abdul
    PLOS ONE, 2014, 9 (01):
  • [22] Curcumin/nido-carborane complexes incorporated with crown ether/ sodium alginate encapsulated drug delivery strategies exhibit pH-responsive release and enhanced in vitro anti-tumor activity
    Chai, Tiantian
    Zhang, Mengtong
    Wang, Shuo
    Feng, Jiankang
    Feng, Xibin
    Shao, Shihe
    Lu, Chichong
    Jin, Guofan
    DYES AND PIGMENTS, 2024, 231
  • [23] Two-component reduction-sensitive lipid-polymer hybrid nanoparticles for triggered drug release and enhanced in vitro and in vivo anti-tumor efficacy
    Zhang, Liu-Jie
    Wu, Bo
    Zhou, Wei
    Wang, Cai-Xia
    Wang, Qian
    Yu, Hui
    Zhuo, Ren-Xi
    Liu, Zhi-Lan
    Huang, Shi-Wen
    BIOMATERIALS SCIENCE, 2017, 5 (01) : 98 - 110
  • [24] In vitro conditioned "early" but not "late" effector CD8+ T cells benefit from transient lymphopenia resulting in enhanced anti-tumor activity
    Diaz-Montero, C. Marcela
    AL-Khami, Amir
    Naga, Osama
    Cole, David
    Salem, Mohamed
    FASEB JOURNAL, 2008, 22
  • [25] The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo
    Nicole Lavender
    Jinming Yang
    Sheau-Chiann Chen
    Jiqing Sai
    C. Andrew Johnson
    Philip Owens
    Gregory D. Ayers
    Ann Richmond
    BMC Cancer, 17
  • [26] The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo
    Lavender, Nicole
    Yang, Jinming
    Chen, Sheau-Chiann
    Sai, Jiqing
    Johnson, C. Andrew
    Owens, Philip
    Ayers, Gregory D.
    Richmond, Ann
    BMC CANCER, 2017, 17
  • [27] In vitro masked effect, in vivo anti-tumor activity and toxicology study of KGX101, an interleukin-12 prodrug, in monotherapy or in combination with anti-PD-L1 antibody
    Yang, Shumin
    Li, Nuo
    Wang, Jing
    Ma, Li
    Zhao, Yi
    Chen, Hui
    Wu, Haixiang
    Jiang, Weidong
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo
    Yan, Jieke
    Wang, Yuzhen
    Zhang, Xufeng
    Liu, Shuangde
    Tian, Chuan
    Wang, Hongwei
    DRUG DELIVERY, 2016, 23 (05) : 1757 - 1762
  • [29] PrevOnco® exhibits anti-tumor activity in in vitro and in vivo human tumor models: Combination therapy (PrevOnco® / Doxorubicin) demonstrates a better efficacy profile with enhanced survival rate in a liver cancer model
    Incardona, Francesca
    Dines, Kevin
    Damaj, Bassam
    Martin, Richard
    Hachicha, Mohamed
    CANCER RESEARCH, 2011, 71
  • [30] New gold(III) complexes TGS 121, 404, and 702 show anti-tumor activity in colitis-induced colorectal cancer: an in vitro and in vivo study
    Wlodarczyk, Jakub
    Krajewska, Julia
    Talar, Marcin
    Szeleszczuk, Lukasz
    Gurba, Agata
    Lipiec, Szymon
    Taciak, Przemyslaw
    Szczepaniak, Remigiusz
    Mlynarczuk-Bialy, Izabela
    Fichna, Jakub
    PHARMACOLOGICAL REPORTS, 2024, 76 (01) : 127 - 139